《新股消息》溫嶺工量刃具(01379.HK)今日起招股 入場費3,409元
內地工量刃具交易中心運營商溫嶺工量刃具(01379.HK)公布招股詳情,計劃發售2,000萬股H股,當中10%在港公開發售,招股價介乎每股6.25元至6.75元,每手500股,入場費為3,409元。由今日(11日)至下周三(16日)公開招股,預計於12月30日上市。信達國際為獨家保薦人。
以招股價中位數6.5元計,公司預計集資所得款項淨額約為6,600萬元,當中70%將用於設立及建設產業園之成本及開支提供部分資金;20%將用於撥付三樓的進一步發展;以及10%用於一般營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.